
Judgment of the Court (Fourth Chamber) of December – Commission v Poland
(Case C-385/08)
Failure of a Member State to fulfil obligations – Accession of new Member States – Marketing authorisations for medicinal products that are generics of the reference product Plavix – Conditional decisions authorising the marketing of pharmaceutical products – Infringement of the acquis
1.                     Actions for failure to fulfil obligations – Subject-matter of the dispute (Art. EC) (see paras 28-33)
2.                     Procedure – Application initiating proceedings – Formal requirements – Identification of the subject-matter of the dispute
            – Brief summary of the pleas in law on which the application is based – Unambiguous wording of the form of order sought by
            the applicant (Rules of Procedure of the Court of Justice, Art. 38(1)(c)) (see paras 34-37)
3.                     Approximation of laws – Medicinal products for human use – Marketing authorisation (Treaty of Accession 2003, Arts and and Annex XII, Chapter 1, para. 5; European Parliament and Council Regulation No 726/2004, Arts and 90; Council Regulation
            No 2309/93, Art. 13(4); European Parliament and Council Directive 2001/83, Art. 6(1)) (see paras 62-70, 77-82, operative part)
            
Re: 
Failure of a Member State to fulfil obligations – Infringement of Article 6(1) of Directive 2001/83/EC of the European Parliament
                  and of the Council of November on the Community code relating to medicinal products for human use (OJ L 311, p.
                  67), read in conjunction with Article 13(4) of Council Regulation (EEC) No 2309/of July laying down Community procedures
                  for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency
                  for the Evaluation of Medicinal Products (OJ L 214, p. 1) and with Articles and of Regulation (EC) No 726/of the European Parliament and of the Council of March laying down Community procedures for the authorisation and
                  supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136,
                  p. 1) – Marketing authorisations for medicinal products that are generics of the reference product Plavix, in breach of the
                  10-year period of protection enjoyed by the latter – Conditional decisions authorising the marketing of pharmaceutical products,
                  issued before the date of Poland’s accession to the European Union but not becoming effective until after that date – Decisions
                  inconsistent with the provisions of Directive 2001/83/EC.
               
Operative part
The Court: 
1.
	Declares that,
–        by retaining in force the decisions of the Minister for Health concerning marketing authorisations for medicinal products
         that are generics of the reference product Plavix, and
      
–        by placing and keeping on the market, after May 2004, medicinal products whose marketing authorisation was not issued in
         accordance with Article 6(1) of Directive 2001/83/EC of the European Parliament and of the Council of November on the
         Community code relating to medicinal products for human use,
      
the Republic of Poland has failed to fulfil its obligations, as regards the first indent above, under Article 6(1) of Directive
         2001/83, in conjunction with Article 13(4) of Council Regulation (EEC) No 2309/of July laying down Community procedures
         for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency
         for the Evaluation of Medicinal Products and with Articles and of Regulation (EC) No 726/of the European Parliament
         and of the Council of March laying down Community procedures for the authorisation and supervision of medicinal products
         for human and veterinary use and establishing a European Medicines Agency and, as regards the second indent above, under Article
         6(1) of Directive 2001/83;
      
2.
	Orders the Republic of Poland to pay the costs;
3.
	Orders the Republic of Lithuania to bear its own costs.
Top  
 